New hope for young patients with rare blood disorder
Disease control
Not yet recruiting
This study aims to see if adding the drug romiplostim to standard immunosuppressive therapy helps children and young adults (ages 2-21) with severe aplastic anemia. The goal is to improve their blood cell counts and reduce the need for transfusions. The main measure of success is…
Phase: PHASE2 • Sponsor: Anjali Sharathkumar • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC